Fri., 10/19/07 Foot & Ankle, Paper #32, 3:15 pm OTA-2007
Brian J. White, MD (n); Kenneth A. Egol, MD (n); Michael Walsh, PhD (n);
Nirmal C. Tejwani, MD (n);
NYU Hospital for Joint Diseases, New York, New York, USA
Fri., 10/19/07 Foot & Ankle, Paper #33, 3:21 pm OTA-2007
Outcome after Unstable Ankle Fracture: Effect of Syndesmotic Stabilization
Kenneth A. Egol, MD (a-Synthes, Stryker, Biomet, Smith+Nephew);
Michael Walsh, PhD (n); Nirmal C. Tejwani, MD (e-Stryker, Biomet);
Kenneth J. Koval, MD (e-Biomet, Stryker);
NYU Hospital for Joint Diseases, New York, New York, USA
Fri., 10/19/07 Foot & Ankle, Paper #34, 3:27 pm OTA-2007
Should the Syndesmosis Screw Be Removed?
Ajay Manjoo, MD1 (n), David W. Sanders MD, MSc2 (n); Christina Tieszer, MSc2 (n);
Mark MacLeod, MD2 (n);
1University of Western Ontario, London, Ontario, Canada;
2Victoria Hospital, University of Western Ontario, London, Ontario, Canada
Fri., 10/19/07 Foot & Ankle, Paper #35, 3:33 pm OTA-2007
William M. Ricci, MD1 (a-Synthes, AONA; a,c,e-Smith+Nephew; e-OrthoVita);
Erica Jantho1 (n); Paul Tornetta, III, MD2 (a,c,e-Smith+Nephew);
Joseph Borrelli, Jr, MD3 (a-Synthes, AONA; e-Wright Medical, Medtronics);
1Washington University School of Medicine, St. Louis, Missouri, USA;
2Boston Medical Center, Boston, Massachusetts, USA;
3University of Texas–Southwestern, Dallas, Texas, USA
Fri., 10/19/07 Foot & Ankle, Paper #36, 3:47 pm OTA-2007
The Results of a Staged Open Treatment Protocol for Pilon Fractures
David E. Asprinio, MD (n); Travis J. Kemp, MD (n); Scott J. Tarantino, MD (n);
Anna Samartzis, MD (n); Paul Lucas, PhD (n);
Westchester Medical Center–New York Medical College, Valhalla, New York, USA
Fri., 10/19/07 Foot & Ankle, Paper #37, 3:53 pm OTA-2007
The Sequential Recovery of Health Status after Tibial Plafond Fractures
J. Lawrence Marsh, MD (n); Todd O. McKinley, MD (n); Douglas R. Dirschl, MD (n);
Andrew G. Pick, BS (n); Geoffrey Haft, MD (n); Donald D. Anderson, PhD (n);
Thomas D. Brown, PhD (n);
University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
If noted, the author indicates something of value received. The codes are identified as a-research or institutional support; b-miscellaneous funding; c-royalties; d-stock options; e-consultant or employee; n-no conflicts disclosed, and *disclosure not available at time of printing.
• The FDA has not cleared this drug and/or medical device for the use described in this presentation (i.e., the drug or medical device is being discussed for an “off label” use). ◆FDA information not available at time of printing.